Sieradzan KA - Search Results

1

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.

Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Sieradzan KA, et al. Neurology. 2001 Dec 11;57(11):2108-11. doi: 10.1212/wnl.57.11.2108. Neurology. 2001. PMID: 11739835 Clinical Trial.

2

Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.

Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM. Sieradzan KA, et al. Exp Neurol. 1999 Mar;156(1):92-9. doi: 10.1006/exnr.1998.7005. Exp Neurol. 1999. PMID: 10192780

3

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network. Cubo E, et al. Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8. Neurology. 2016. PMID: 27402890

4

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators; Holmans P, Jones L, Tabrizi SJ. Moss DJH, et al. Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Lancet Neurol. 2017. PMID: 28642124

5

Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry.

Sen A, Verner R, Valeriano JP, Lee R, Zafar M, Thomas R, Kotulska K, Jespers E, Dibué M, Kwan P; CORE-VNS Registry Group. Sen A, et al. BMJ Neurol Open. 2021 Dec 23;3(2):e000218. doi: 10.1136/bmjno-2021-000218. eCollection 2021. BMJ Neurol Open. 2021. PMID: 35018342 Free PMC article.

6

Late-onset Pompe disease primarily affects quality of life in physical health domains.

Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Hagemans ML, et al. Among authors: sieradzan ka. Neurology. 2004 Nov 9;63(9):1688-92. doi: 10.1212/01.wnl.0000142597.69707.78. Neurology. 2004. PMID: 15534256

7

Clinical presentation and patterns of regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease.

Sieradzan K, Mann DM, Dodge A. Sieradzan K, et al. Neurosci Lett. 1997 Mar 28;225(1):45-8. doi: 10.1016/s0304-3940(97)00182-1. Neurosci Lett. 1997. PMID: 9143014 Clinical Trial.

8

The selective vulnerability of nerve cells in Huntington's disease.

Sieradzan KA, Mann DM. Sieradzan KA, et al. Neuropathol Appl Neurobiol. 2001 Feb;27(1):1-21. doi: 10.1046/j.0305-1846.2001.00299.x. Neuropathol Appl Neurobiol. 2001. PMID: 11298997 Review.

9

On the pathological progression of Huntington's disease.

Sieradzan KA, Mann DM. Sieradzan KA, et al. Ann Neurol. 1998 Jul;44(1):148-9. doi: 10.1002/ana.410440127. Ann Neurol. 1998. PMID: 9667607 No abstract available.

10

Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.

McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. McNulty P, et al. J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263. J Huntingtons Dis. 2018. PMID: 30103338

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters